Kuros Biosciences Appoints Chief Medical Officer

Schlieren (Zurich), Switzerland, March 8, 2016 – Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect.

Dr. Jamieson has spent over 25 years in the pharmaceutical industry and has considerable experience in early and late stage clinical development, product registration and medical affairs. Dr. Jamieson received her medical degree at Edinburgh University and obtained a postgraduate fellowship in anesthesia from the Royal College of Surgeons in London. In addition, she has a diploma from the Faculty of Pharmaceutical Medicine where she has also been an appraiser for revalidation of physicians in the pharmaceutical industry. Dr. Jamieson already worked for Kuros from 2005 to 2012 as Medical Director and then as Chief Medical Officer and is therefore very familiar with Kuros’ products.

Didier Cowling, CEO of Kuros, said: “We are delighted to have Virginia join us again. Her wealth of experience, both in the surgical field and pharmaceutical and medical industry, coupled with her deep knowledge of Kuros’ products, makes this a key appointment for us.”

For further information, please contact:

Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol KURN.

Back to news